Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANAVEX 3-71

Next Previous
Drug Profile

ANAVEX 3-71

Alternative Names: AF-710B; ANAVEX-3-71

Latest Information Update: 07 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Life Science Research Israel
  • Developer Anavex Life Sciences; Life Science Research Israel
  • Class Anti-inflammatories; Antidementias; Antiparkinsonians; Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Muscarinic M1 receptor agonists; Sigma-1 receptor agonists; Sigma-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dementia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia
  • Phase I Alzheimer's disease; Frontotemporal dementia; Neurodegenerative disorders
  • No development reported Parkinson's disease

Most Recent Events

  • 07 Oct 2025 Phase-I development is ongoing in USA (Anavex Life Sciences pipeline, October 2025)
  • 07 Oct 2025 Phase-I clinical trials in Alzheimer's disease in USA (PO) (Anavex Life Sciences pipeline, October 2025)
  • 02 Oct 2025 Pharmacodynamics and adverse events data from a phase II trial in Schizophrenia released by Anavex Life Sciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top